Clement J G, Simons K J, Briggs C J
Biomedical Defence Section, Defence Research Establishment Suffield, Ralston, Alberta, Canada.
Biopharm Drug Dispos. 1988 Mar-Apr;9(2):177-86. doi: 10.1002/bod.2510090206.
The effect of fasting, atropine, and poisoning by an organophosphate anticholinesterase soman (pinacolyl methylphosphonofluoridate) on the pharmacokinetics of the acetylcholinesterase oxime reactivator HI-6 (CAS Reg. No. 34433-31-3; 1-[(4-(aminocarbonyl)pyridinio)methoxy)methyl)-2-(hydroxy imino)methyl) pyridinium dichloride) was investigated. Pharmacokinetic parameters (elimination half-life, volume of distribution, clearance rate) were determined for the following groups: (1) a 20 and 50 mg kg-1 dose of HI-6; (2) a 50 mg kg-1 dose of HI-6 after fasting for 18 h (water ad lib); (3) a 50 mg kg-1 dose of HI-6 at 0, 4, and 24 h after atropine (17.4 mg kg-1, i.p.) and soman (287 micrograms kg-1, s.c.); and (4) a 50 mg kg-1 dose of HI-6 at 0 and 4 h after soman (100 micrograms kg-1, s.c.). Fasting increased significantly (p less than 0.05) the elimination of half-life (t1/2) and tended to increase the volume of distribution (Vd) and decrease the clearance rate (CL). Following soman (287 micrograms kg-1) poisoning the t1/2 of HI-6 increased from 8.6 min to 21.6 min and the Vd increased to 0.731 kg-1. At the lower soman dose (100 micrograms kg-1) no significant effect on HI-6 pharmacokinetics was found. Atropine (17.4 mg kg-1: i.p.) pretreatment increased the t1/2 and CL while having no effect on the Vd. By 24 h the pharmacokinetic parameters of HI-6 in the various treatment groups were not significantly different from the control group. The changes in the pharmacokinetics of HI-6 following soman and atropine are probably the result of haemodynamic changes.
研究了禁食、阿托品以及有机磷酸酯类抗胆碱酯酶梭曼(频哪基甲基膦酰氟)中毒对乙酰胆碱酯酶肟类重活化剂HI-6(化学物质登记号:34433-31-3;1-[(4-(氨基甲酰基)吡啶鎓)甲氧基)甲基]-2-(羟基亚氨基)甲基)吡啶二氯化物)药代动力学的影响。测定了以下几组的药代动力学参数(消除半衰期、分布容积、清除率):(1) 20和50 mg kg-1剂量的HI-6;(2) 禁食18小时(随意饮水)后50 mg kg-1剂量的HI-6;(3) 在阿托品(17.4 mg kg-1,腹腔注射)和梭曼(287微克 kg-1,皮下注射)后0、4和24小时给予50 mg kg-1剂量的HI-6;以及(4) 梭曼(100微克 kg-1,皮下注射)后0和4小时给予50 mg kg-1剂量的HI-6。禁食显著增加(p小于0.05)消除半衰期(t1/2),并倾向于增加分布容积(Vd)和降低清除率(CL)。梭曼(287微克 kg-1)中毒后,HI-6的t1/2从8.6分钟增加到21.6分钟,Vd增加到0.731 kg-1。在较低剂量的梭曼(100微克 kg-1)时,未发现对HI-6药代动力学有显著影响。阿托品(17.4 mg kg-1:腹腔注射)预处理增加了t1/2和CL,而对Vd无影响。到24小时时,各治疗组中HI-6的药代动力学参数与对照组无显著差异。梭曼和阿托品作用后HI-6药代动力学的变化可能是血流动力学变化的结果。